CancerVax Corp. (Nasdaq: CNVX) has agreed to merge with Micromet AG, a Germany-based antibody developer, for about $126.7 million.
In: Private Equity Week, Jg. 13 (2006-01-17), Heft 2, S. 1
serialPeriodical
Zugriff:
Titel: |
CancerVax Corp. (Nasdaq: CNVX) has agreed to merge with Micromet AG, a Germany-based antibody developer, for about $126.7 million.
|
---|---|
Zeitschrift: | Private Equity Week, Jg. 13 (2006-01-17), Heft 2, S. 1 |
Veröffentlichung: | 2006 |
Medientyp: | serialPeriodical |
ISSN: | 1099-341X (print) |
Sonstiges: |
|